news
Sanofi invests $180 million in Owkin’s AI to advance oncology pipeline
Sanofi invests $180 million equity in Owkin’s artificial intelligence (AI) and federated learning to advance oncology pipeline.
List view / Grid view
Multiple myeloma
podcasts
EPR Podcast Episode 6 – Precision Medicine with Laetitia Decroix Guilloux and Edmond Chan, Janssen
Why are precision medicines important? What challenges face their development and manufacture? Where could they be in 10 years? Discover all this and more in this podcast with Janssen!
news
Personalised cancer vaccine safe and potentially beneficial to patients
Mount Sinai researchers reveal that, in a Phase I trial, their personalised cancer vaccines targeting cancer neoantigens showed some early signs of potential benefit.
news
FDA approves Abecma, the first cell-based gene therapy for adults with multiple myeloma
Abecma (idecabtagene vicleucel) was approved for adults with relapsed or refractory myeloma based on its 72 percent overall response rate in a trial.
news
NICE recommends new triple therapy treatment for multiple myeloma
Carfilzomib with dexamethasone and lenalidomide could be offered to approximately 2,000 NHS patients as a second line treatment for multiple myeloma.
news
EMA recommends 15 medicines for approval following December meeting
The EMA's human medicines committee has released its results for the December meeting, suggesting which therapies should receive marketing authorisation.
news
EMA recommends 10 medicines for approval in October meeting
Ten medicines have been recommended for marketing authorisation and 10 extensions of indication have been suggested by the EMA.
news
Blenrep granted CMA for relapsed or refractory multiple myeloma
The European Commission granted the conditional marketing authorisation (CMA) based on data from a trial in which Blenrep achieved an overall response rate of 32 percent.
news
EMA recommends 11 new medicines for approval following July meeting
Dapivirine Vaginal Ring (dapivirine) and Blenrep (belantamab mafodotin) have been recommended for approval by the EMA's CHMP, along with nine other medicines.
article
The many advantages of repurposing existing drugs
Repurposing existing drugs can be attractive as the process is often less risky, more cost effective and can be undertaken in less time. This article discusses the logic behind drug repurposing and the approaches that are currently being explored.
news
Committee for Medicinal Products for Human Use (CHMP) meeting highlights
A summary of the CHMP meeting conclusions, including medicines recommended for approval and indication extension and several safety review findings.
article
Five of the most recent developments in anti-cancer therapeutics
European Pharmaceutical Review investigates five of the latest cancer drug approvals and clinical trial results.
news
Multiple myeloma treatment receives IND from FDA
The FDA has granted Investigational New Drug (IND) authorisation to KP1237 for the treatment of multiple myeloma using a patient's own Natural Killer cells.
news
EC approves Darzalex® in combination with VTd for multiple myeloma
The European Commission (EC) granted marketing authorisation for Darzalex in combination with bortezomib, thalidomide and dexamethasone (VTd) for multiple myeloma patients.
article
Top 10 drugs by annual revenue in 2025
Researchers have revealed the top 10 drugs by annual revenue in 2025. Here, we investigate the indications that necessitate these treatments and the delivery systems they employ.
